Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation
Open Access
- 23 February 2017
- journal article
- Published by American Society of Hematology in Blood
- Vol. 129 (8) , 970-980
Abstract
Key Points: Strong complement activation overrides the terminal pathway inhibition by the anti-C5 antibody eculizumab. The more powerful complement is activated, the less effective is terminal pathway inhibition by diverse anti-C5 agents.Keywords
This publication has 58 references indexed in Scilit:
- PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteinsProtein Engineering, Design and Selection, 2013
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- Structural Analysis of the C-Terminal Region (Modules 18–20) of Complement Regulator Factor H (FH)PLOS ONE, 2012
- Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseasesBlood, 2011
- Red blood cell preservation by droplet freezing with polyvinylpyrrolidone or sucrose‐dextrose and by bulk freezing with glycerolTransfusion, 2011
- Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytesAnnals of Hematology, 2011
- Complement: a key system for immune surveillance and homeostasisNature Immunology, 2010
- Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonizationHaematologica, 2010
- Translational Mini-Review Series on Complement Factor H: Structural and functional correlations for factor HClinical and Experimental Immunology, 2007
- Factor H–mediated cell surface protection from complement is critical for the survival of PNH erythrocytesBlood, 2007